KENNEDY CAPITAL MANAGEMENT LLC

Position in CLDX — Celldex Therapeutics, Inc.

CIK 884589 ST LOUIS, MO

Position in CLDX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$12,738,024

+$1,563,005 QoQ

Shares Held

342,328

-2.8% QoQ

Ownership

0.436%

of shares outstanding

% of Portfolio

0.23%

of 13F equity value

Holder Rank

#51

of 252 holders

Holding Since

Dec 2021

12 quarters on record

Voting authority Sole 93% Shared 0% None 7%

Healthcare · as of Jun 30, 2026

KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. CLDX ranks #12 (2.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	HALO	Halozyme Therapeutics, Inc.	544,994	$42,656,680
2	RYTM	Rhythm Pharmaceuticals, Inc.	193,215	$21,452,661
3	NRIX	Nurix Therapeutics, Inc.	724,508	$17,576,564
4	CORT	Corcept Therapeutics Inc	201,979	$17,562,074
5	PTGX	Protagonist Therapeutics, Inc	134,019	$16,428,049
6	MGTX	MeiraGTx Holdings plc	1,105,421	$14,934,237
7	ADMA	Adma Biologics, Inc.	1,755,152	$14,690,622
8	NAMS	NewAmsterdam Pharma Co N.V.	421,374	$14,280,364

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$12,738,024	342,328	-2.8%	Shares	Sole	2026-08-14
2026-03-31	$11,175,019	352,302	+949.0%	Shares	Sole	2026-05-13
2024-03-31	$1,409,604	33,586	-46.0%	Shares	Sole	2024-05-15
2023-12-31	$2,465,741	62,172	-28.9%	Shares	Sole	2024-02-14
2023-09-30	$2,405,082	87,394	+0.2%	Shares	Sole	2023-11-14
2023-06-30	$2,959,646	87,228	+7.2%	Shares	Sole	2023-08-14
2023-03-31	$2,927,548	81,366	+0.1%	Shares	Sole	2023-05-15
2022-12-31	$3,624,387	81,319	-0.0%	Shares	Sole	2023-02-14
2022-09-30	$2,286,748	81,350	+234.6%	Shares	Sole	2022-11-14
2022-06-30	$655,559	24,316	-0.8%	Shares	Sole	2022-08-10
2022-03-31	$835,049	24,517	-12.9%	Shares	Sole	2022-05-16
2021-12-31	$1,088,025	28,158	—	Shares	Sole	2022-02-14
No filing history on record for this holder in this stock.